|Dr. Phillip Schwartz Ph.D.||CEO & Director||362.56k||N/A||1962|
|Dr. Hillel Galitzer||Chief Operating Officer||235.67k||N/A||1978|
|Dr. Roger J. Garceau||Chief Devel. Advisor & Director||108.92k||N/A||1954|
|Dr. Arthur C. Santora II||Chief Medical Officer||N/A||N/A||N/A|
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.
Entera Bio Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.